GlassScriptPhysician profile
John R Adams
NPI 1922006410
$9,672.75
in general payments reported to CMS, 2019-2025
62 companies · $1,729 in 2025
The $1,729 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $879 · 2020: $1,059 · 2021: $1,291 · 2022: $1,372 · 2023: $1,555 · 2024: $1,787 · 2025: $1,729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,071.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,995.46 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $1,270.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $663.31 | 2019-2025 | Airsupra |
| Amgen INC. | $630.77 | 2019-2025 | Repatha, Evenity, Otezla |
| Amarin Pharma, INC. | $549.58 | 2019-2023 | |
| Glaxosmithkline, LLC. | $432.37 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $410.39 | 2021-2023 | Qulipta, Ubrelvy, Linzess |
| Lilly USA, LLC | $390.07 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $356.33 | 2019-2025 | Jardiance, Ofev, Synjardy |
| Pfizer INC. | $348.43 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $288.24 | 2021-2024 | Dupixent |
| Kowa Pharmaceuticals America, INC. | $227.63 | 2020-2025 | Livalo, Zoryve |
| Corcept Therapeutics | $197.63 | 2024-2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $193.11 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.93 | 2020-2024 | Xifaxan |
Show all 56 companies
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.